



Stabilis



Moxifloxacin



Noms commerciaux

Actira	Espagne, Luxembourg, Pays bas, Suède
Avalox	Allemagne, Arabie Saoudite, Brésil, Egypte, Emirats Arabes Unis, Italie, Suisse
Axokine	Vénézuela
Mahaflox	Inde
Mofelox	Turquie
Moflaxa	Roumanie
Moksefen	Turquie
Moksilox	Turquie
Moxacin	Turquie
Moxifix	Turquie
Octegra	Pays bas
Pixiriv	Mexique
Praiva	Equateur, Mexique, Pérou
Proflox	Equateur, Luxembourg



Stabilité des solutions

PVC	Δ [®] P1 ◆ 1.36	0.025 mg/ml	25°C	?	7	☐		2145
PVC	Δ [®] P1 ◆ 1.36	0.025 mg/ml	37°C	?	3	☐		2145
PVC	Δ [®] P1 ◆ 1.36	0.025 mg/ml	4°C	?	14	☐		2145
PVC	Δ [®] P1 ◆ 3.86	0.025 mg/ml	25°C	?	3	☐		2145
PVC	Δ [®] P1 ◆ 3.86	0.025 mg/ml	37°C	?	12	☑		2145
PVC	Δ [®] P1 ◆ 3.86	0.025 mg/ml	4°C	?	14	☐		2145
?	◆	1,6 mg/ml	22-23°C		24	☑		4758



Stabilité en mélange

								
		0,8 mg/ml	25°C		Norepinephrine bitartrate : 0,032 mg/ml	4		3865
		8 mg/ml	22-23°C		Norepinephrine bitartrate : 0,032 mg/ml	24		4758



Facteur influençant la stabilité

	4°C			3109 3162
--	-----	--	--	--------------



Compatibilités


	Moxifloxacin : 1,6 mg/ml Norepinephrine bitartrate : 0,064 mg/ml	3865
	Moxifloxacin Sodium bicarbonate : 42 & 84 mg/ml	3109
	Moxifloxacin	3109
	Moxifloxacin	RL 3109
	Moxifloxacin : 1,6 mg/ml Ceftaroline fosamil : 2,22 mg/ml	RL 3249
	Moxifloxacin : 1.6 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL 2269
	Moxifloxacin	3109
	Moxifloxacin : 1.6 mg/ml Vancomycin hydrochloride : 10 mg/ml	3385
	Moxifloxacin	3109
	Moxifloxacin : 1,6 mg/ml Ceftaroline fosamil : 2,22 mg/ml	3249
	Moxifloxacin : 1.6 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	2269
	Moxifloxacin Ceftobiprole medocaril sodium	4650
	Moxifloxacin : 1,6 mg/ml Doripenem : 5 mg/ml	2262
	Moxifloxacin Sodium bicarbonate	3162
	Moxifloxacin : 1.6 mg/ml Temocilline : 83.33 mg/ml	2231
	Moxifloxacin : 1.6 mg/ml Vasopressin : 0.2 UI/ml	2017
	Moxifloxacin	3109




Bibliographie

	Type	Source
2017	Revue	Barker B, Feddema S, Rusho WJ, Dengg R. Visual compatibility of vasopressin with other injectable drugs. Am J Health-Syst Pharm 2005 ; 62: 1969-1976.
2145	Revue	Fernandez-Varon E, Marin P, Espuny A, Villamayor L, Escudero E, Carceles C. Stability of moxifloxacin injection in peritoneal dialysis solution bags (Dianeal PD1 1.36%® and Dianeal PD1 3.86%®). J Clin Pharm Ther 2006 ; 31: 641-643.
2231	Revue	de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008 ; 61, 2: 382-388.
2262	Revue	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administration Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Revue	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
3109	Laboratoire	Moxifloxacin (Izilox®) -Notice information Bayer Schering Pharma 2010
3162	Laboratoire	Moxifloxacin (Izilox®) - Résumé des caractéristiques du produits Bayer HealthCare 2010
3249	Revue	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3385	Revue	Raverdi V, Ampe E, Hecq JD, Tulkens PM. Stability and compatibility of vancomycin for administration by continuous infusion. J Antimicrob Chemother 2013 ; 68: 1179-1182.
3865	Revue	Vicky M, Samit S, Jaymin P, Michael C T. Compatibility of Norepinephrine Bitartrate with Levofloxacin and Moxifloxacin During Simulated Y-site Administration. Int J Pharm Compound 2016 ; 20, 3 : 236-238.
4650	Laboratoire	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021
4758	Revue	Schmidt J.P, Steppe M. Stability Study and Simultaneous Determination of Norepinephrine, Moxifloxacin, and Piperacillin + Tazobactam Mixtures Applied in Intensive Care Medicine . Curr Pharm Anal 2023 ; 19, 4: 307-316.

Stabilis



Moxifloxacin



Stabilité des préparations

		1200 mg Avelox®	OraPlus® / OraSweet® (1:1) >> 60 ml 23-25°C		90			2394
		1200 mg Avelox®	OraPlus® / OraSweet SF® (1:1) >> 60 ml 23-25°C		90			2394



Bibliographie

	Type	Source
2394	Revue	Hutchinson DJ, Johnson CE, Klein KC. Stability of extemporaneously prepared moxifloxacin oral suspensions Am J Health-Syst Pharm 2009 ; 66: 665-667.



Dictionnaire

	Antibiotique		injectable
	Noms commerciaux		Stabilité des solutions
	Contenant		Molécule
	Concentration		Température
	Conservation		Durée de stabilité
	Biosimilaire		Données conflictuelles
	Bibliographie		Polyvinyl chlorure
	Dianéal® PD1 1.36% glucose (Baxter)		Non précisée
	Jour		Dianéal® PD1 3.86% glucose (Baxter)
	Heure		Non précisé
	Glucose 5%		A l'abri de la lumière
	Stabilité en mélange		Solvant
	Molécule		Verre
	Polypropylène		NaCl 0,45% Glucose 2,5%
	Facteur influençant la stabilité		Provoque
	Précipitation		Compatibilités
	Compatible		Incompatibilité non précisée
	Incompatible		Glucose 10%
RL	Ringer lactate		Précipitation immédiate
	Chlorure de sodium 0,9%		NaCl 0,9% ou glucose 5%
	Eau pour préparation injectable		NaHCO3
	Voie d'administration		Perfusion intraveineuse
	Bibliographie		Solution buvable
	Stabilité des préparations		Origine
	Excipient		Flacon plastique
	Comprimés		Dictionnaire